{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:03:51Z","timestamp":1766023431799,"version":"3.48.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Exp Urol"],"DOI":"10.62347\/egwc8899","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T06:02:51Z","timestamp":1756879371000},"page":"284-293","source":"Crossref","is-referenced-by-count":0,"title":["Renal cell carcinoma with unusual morphological features: the clinical utility of next-generation sequencing in distinguishing renal cell tumors"],"prefix":"10.62347","volume":"13","author":[{"given":"Jennifer","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.","DOI":"10.3322\/caac.21820"},{"key":"ref1","unstructured":"Amin MB, Gill AJ, Hartmann A, Lazar AJ, Moch H, Tickoo SK and Turajlic S. Renal cell tumours: Introduction. In WHO Classification of Tumours. Urinary and Male Genital Tumours. 5th ed. International Agency for Research on Cancer; Lyon, France: 2022."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.hoc.2023.04.019","article-title":"Renal cell carcinoma of variant histology: biology and therapies","volume":"37","author":"Msaouel","year":"2023","unstructured":"Msaouel P, Genovese G and Tannir NM. Renal cell carcinoma of variant histology: biology and therapies. Hematol Oncol Clin North Am 2023; 37: 977-992.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"9276","DOI":"10.3390\/curroncol30100670","article-title":"Genomic profiling and molecular characterization of clear cell renal cell carcinoma","volume":"30","author":"Pezzicoli","year":"2023","unstructured":"Pezzicoli G, Ciciriello F, Musci V, Salonne F, Ragno A and Rizzo M. Genomic profiling and molecular characterization of clear cell renal cell carcinoma. Curr Oncol 2023; 30: 9276-9290.","journal-title":"Curr Oncol"},{"key":"ref4","unstructured":"Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA and Zuna R. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016; 374: 135-45."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/PAS.0000000000001629","article-title":"Contemporary characterization and recategorization of adult unclassified renal cell carcinoma","volume":"45","author":"Kwon","year":"2021","unstructured":"Kwon R, Argani P, Epstein JI, Lombardo KA, Wang X, Pierorazio PM, Mehra R and Matoso A. Contemporary characterization and recategorization of adult unclassified renal cell carcinoma. Am J Surg Pathol 2021; 45: 450-462.","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, Concepcion AD, Tang Y, Bai X, Dewal N, Ma P, Bailey ST, Thornton J, Pavlick DC, Frampton GM, Lieber D, White J, Burns C and Vietz C. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 2022; 17: e0264138.","DOI":"10.1371\/journal.pone.0264138"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/his.13311","article-title":"Clear cell renal cell carcinoma: validation of World Health Organization\/International Society of Urological Pathology grading","volume":"71","author":"Dagher","year":"2017","unstructured":"Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J and Samaratunga H. Clear cell renal cell carcinoma: validation of World Health Organization\/International Society of Urological Pathology grading. Histopathology 2017; 71: 918-925.","journal-title":"Histopathology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41379-019-0283-z","article-title":"Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis","volume":"32","author":"Yang","year":"2019","unstructured":"Yang B, Duan H, Cao W, Guo Y, Liu Y, Sun L, Zhang J, Sun Y and Ma Y. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis. Mod Pathol 2019; 32: 1521-1535.","journal-title":"Mod Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"151871","DOI":"10.1016\/j.anndiagpath.2021.151871","article-title":"Clear cell renal cell carcinoma with prominent microvascular hyperplasia: morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases","volume":"56","author":"Alaghehbandan","year":"2022","unstructured":"Alaghehbandan R, Limani R, Ali L, Rogala J, Vanecek T, Steiner P, Hajkova V, Kuthi L, Slisarenko M, Michalova K, Pivovarcikova K, Hora M, Pitra T, Michal M and Hes O. Clear cell renal cell carcinoma with prominent microvascular hyperplasia: morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases. Ann Diagn Pathol 2022; 56: 151871.","journal-title":"Ann Diagn Pathol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/PAP.0000000000000220","article-title":"Papillary renal cell carcinoma (PRCC): an update","volume":"26","author":"Akhtar","year":"2019","unstructured":"Akhtar M, Al-Bozom IA and Al Hussain T. Papillary renal cell carcinoma (PRCC): an update. Adv Anat Pathol 2019; 26: 124-132.","journal-title":"Adv Anat Pathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.anndiagpath.2013.05.004","article-title":"Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics","volume":"17","author":"Pramick","year":"2013","unstructured":"Pramick M, Ziober A and Bing Z. Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics. Ann Diagn Pathol 2013; 17: 437-440.","journal-title":"Ann Diagn Pathol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/modpathol.2012.204","article-title":"Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile","volume":"26","author":"Williamson","year":"2013","unstructured":"Williamson SR, Eble JN, Cheng L and Grignon DJ. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol 2013; 26: 697-708.","journal-title":"Mod Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5858\/arpa.2011-0479-RA","article-title":"Renal cell carcinoma with clear cell and papillary features","volume":"136","author":"Ross","year":"2012","unstructured":"Ross H, Martignoni G and Argani P. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med 2012; 136: 391-399.","journal-title":"Arch Pathol Lab Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/00313021003785746","article-title":"Differential diagnosis of renal tumours with clear cell histology","volume":"42","author":"Reuter","year":"2010","unstructured":"Reuter VE and Tickoo SK. Differential diagnosis of renal tumours with clear cell histology. Pathology 2010; 42: 374-383.","journal-title":"Pathology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/PAS.0b013e31818649ed","article-title":"Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis","volume":"32","author":"Gobbo","year":"2008","unstructured":"Gobbo S, Eble JN, Maclennan GT, Grignon DJ, Shah RB, Zhang S, Martignoni G, Brunelli M and Cheng L. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol 2008; 32: 1780-1786.","journal-title":"Am J Surg Pathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"155090","DOI":"10.1016\/j.prp.2024.155090","article-title":"Aggressive renal cell carcinoma with biphasic papillary and solid clear cell features harboring IDH2 (R172M) mutation","volume":"253","author":"Zhao","year":"2024","unstructured":"Zhao M, Xia Y and Wang W. Aggressive renal cell carcinoma with biphasic papillary and solid clear cell features harboring IDH2 (R172M) mutation. Pathol Res Pract 2024; 253: 155090.","journal-title":"Pathol Res Pract"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41585-024-00876-w","article-title":"Von hippel-lindau protein signalling in clear cell renal cell carcinoma","volume":"21","author":"Liao","year":"2024","unstructured":"Liao C, Hu L and Zhang Q. Von hippel-lindau protein signalling in clear cell renal cell carcinoma. Nat Rev Urol 2024; 21: 662-675.","journal-title":"Nat Rev Urol"},{"key":"ref18","unstructured":"Elias R, Sharma A, Singla N and Brugarolas J. Next generation sequencing in renal cell carcinoma: towards precision medicine. Kidney Cancer J 2019; 17: 94-104."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1038\/s41467-024-49692-1","article-title":"Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma","volume":"15","author":"Culliford","year":"2024","unstructured":"Culliford R, Lawrence SED, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A and Pallikonda H. Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nat Commun 2024; 15: 5935.","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.eururo.2023.04.003","article-title":"Current landscape of genomic biomarkers in clear cell renal cell carcinoma","volume":"84","author":"Cotta","year":"2023","unstructured":"Cotta BH, Choueiri TK, Cieslik M, Ghatalia P, Mehra R, Morgan TM, Palapattu GS, Shuch B, Vaishampayan U, Van Allen E, Ari Hakimi A and Salami SS. Current landscape of genomic biomarkers in clear cell renal cell carcinoma. Eur Urol 2023; 84: 166-175.","journal-title":"Eur Urol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49.","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41585-022-00659-1","article-title":"PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma","volume":"20","author":"Walton","year":"2023","unstructured":"Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C and Ailles L. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Nat Rev Urol 2023; 20: 96-115.","journal-title":"Nat Rev Urol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers12010016","article-title":"Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma","volume":"12","author":"Carril-Ajuria L","year":"2019","unstructured":"Carril-Ajuria L, Santos M, Roldán-Romero JM, Rodriguez-Antona C and de Velasco G. Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers (Basel) 2019; 12: 16.","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Högner A, Krause H, Jandrig B, Kasim M, Fuller TF, Schostak M, Erbersdobler A, Patzak A and Kilic E. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient’s overall survival. Urol Oncol 2018; 36: 94.e1-94.e14.","DOI":"10.1016\/j.urolonc.2017.10.027"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","unstructured":"Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ and Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14: 159-167.","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.clgc.2021.03.003","article-title":"Prognostic impact of loss of SETD2 in clear cell renal cell carcinoma","volume":"19","author":"VE","year":"2021","unstructured":"Santos VE, da Costa WH, Bezerra SM, da Cunha IW, Nobre JQC, Brazão ES Jr, Meduna RR, Rocha MM, Fornazieri L and Zequi SC. Prognostic impact of loss of SETD2 in clear cell renal cell carcinoma. Clin Genitourin Cancer 2021; 19: 339-345.","journal-title":"Clin Genitourin Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.juro.2010.09.013","article-title":"Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features","volume":"185","author":"Klatte","year":"2011","unstructured":"Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS and Pantuck AJ. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol 2011; 185: 30-35.","journal-title":"J Urol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-08-1229","article-title":"Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma","volume":"15","author":"Klatte","year":"2009","unstructured":"Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF and Belldegrun AS. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15: 1162-1169.","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cancergencyto.2010.02.013","article-title":"Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma","volume":"199","author":"Antonelli","year":"2010","unstructured":"Antonelli A, Tardanico R, Balzarini P, Arrighi N, Perucchini L, Zanotelli T, Cozzoli A, Zani D, Cunico SC and Simeone C. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet 2010; 199: 128-133.","journal-title":"Cancer Genet Cytogenet"},{"key":"ref30","unstructured":"Yeh YA, Constantinescu M, Chaudoir C, Tanner A, Serkin F, Yu X, Fazili T and Lurie AA. Renal cell carcinoma with leiomyomatous stroma: a review of an emerging entity distinct from clear cell conventional renal cell carcinoma. Am J Clin Exp Urol 2019; 7: 321-326."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/PAS.0000000000001255","article-title":"Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma","volume":"43","author":"Parilla","year":"2019","unstructured":"Parilla M, Alikhan M, Al-Kawaaz M, Patil S, Kadri S, Ritterhouse LL, Segal J, Fitzpatrick C and Antic T. Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma. Am J Surg Pathol 2019; 43: 1135-1144.","journal-title":"Am J Surg Pathol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/PAS.0000000000001422","article-title":"“Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and\/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity","volume":"44","author":"Shah","year":"2020","unstructured":"Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K and McKenney JK. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and\/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol 2020; 44: 571-581.","journal-title":"Am J Surg Pathol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.humpath.2022.12.015","article-title":"TSC\/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases","volume":"134","author":"Tjota","year":"2023","unstructured":"Tjota MY, Sharma A, Wanjari P, Fitzpatrick C, Segal J and Antic T. TSC\/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol 2023; 134: 124-133.","journal-title":"Hum Pathol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1586\/14737159.2015.1068122","article-title":"BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies","volume":"15","author":"Piva","year":"2015","unstructured":"Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S and Montironi R. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn 2015; 15: 1201-1210.","journal-title":"Expert Rev Mol Diagn"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.anndiagpath.2018.11.004","article-title":"Papillary pattern in clear cell renal cell carcinoma: clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases","volume":"38","author":"Alaghehbandan","year":"2019","unstructured":"Alaghehbandan R, Ulamec M, Martinek P, Pivovarcikova K, Michalova K, Skenderi F, Hora M, Michal M and Hes O. Papillary pattern in clear cell renal cell carcinoma: clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases. Ann Diagn Pathol 2019; 38: 80-86.","journal-title":"Ann Diagn Pathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA and Motter A. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022; 20: 71-90.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Arduini D, Ciccarese C, Strusi A, Beccia V, Pedone RR, Scala A, Sardaro V, Tortora G and Iacovelli R. The clinical role of hypoxia inducible factor (HIF) inhibition in renal cancer: a focus on belzutifan. Curr Cancer Drug Targets 2025; [Epub ahead of print].","DOI":"10.2174\/0115680096323507241101064127"}],"container-title":["American Journal of Clinical and Experimental Urology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajceu\/13\/4\/ajceu0165089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:59:01Z","timestamp":1766023141000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajceu\/13\/4\/ajceu0165089.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/egwc8899","relation":{},"ISSN":["2330-1910"],"issn-type":[{"type":"electronic","value":"2330-1910"}],"subject":[],"published":{"date-parts":[[2025]]}}}